On the first day of the Hungry Ghost Month last Saturday (Aug 23), a group of devotees in Sembawang struck it big after betting on a 'lucky' 4D number posted at the prayer altar. The 'lucky' number ...

You know, Bubsy, the talking orange bobcat mascot from the 90s? He's back, with a new 3D game developed by indie studio Fabraz and published by Atari. It's called Bubsy 4D, and it's Bubsy's first 3D ...

Investing.com -- Warehouses de Pauw (EBR:WDPP) (EBR:WDP) on Friday reported its H1 2025 results, confirming its full-year guidance despite slightly softening operational metrics and increasing ...

Investing.com - Berenberg has upgraded WDP NV/SA (BR:WDP) from Hold to Buy while lowering its price target to EUR27.00 from EUR31.00, citing an attractive entry point after the stock’s 30% decline in ...

4D Molecular Therapeutics laid off a quarter of its workforce last month with early-stage R&D bearing the brunt of the changes. The genetic medicines biotech said shrinking its headcount by 25% should ...

Looking for the most recent Wordle answer? Click here for today's Wordle hints, as well as our daily answers and hints for The New York Times Mini Crossword, Connections, Connections: Sports Edition ...

3D and 4D ultrasounds are optional. They're not standard prenatal tests. Doctors often give them as a courtesy to women who want them. Not all doctors have access to 3D or 4D ultrasounds. Also, your ...

The Man Who Charmed the Women on The View, & Singing for the Poor in Rome Medicine at Michigan Shamefully Honors Jack Kevorkian Delighting in Certain Violence: Guarding Our Souls in the 2025 USA Memo ...

In April 1982, Prof. Dan Shechtman of the Technion–Israel Institute of Technology made the discovery that would later earn him the 2011 Nobel Prize in Chemistry: the quasiperiodic crystal. According ...

Please provide your email address to receive an email when new articles are posted on . Patients who received 4D-150 3E10 vg/eye experienced an 8.4 letter increase in BCVA. 4DMT is progressing to a ...

4D Molecular Therapeutics is axing two clinical programs and cutting off funds for three other assets, with resources to be pivoted toward launching late-stage studies for the biotech's eye disease ...